USC finds the needle in the haystack with molecular imaging

Clinicians may one day be able to snap an iPhone picture of a suspicious mole and use a USC-developed technique to determine it’s cancer risk, according to an article published in Nature Methods.

Known as Hyper-Spectral Phasor Analyiis (HySP), the technique uses fluorescent imaging to tag molecules, similar to PET imaging. However, HySP can pick out several different types of molecules at once, giving doctors and researchers a more complete picture.

“Biological research is moving toward complex systems that extend across multiple dimensions, the interaction of multiple elements over time,” said postdoctoral fellow Francesco Cutrale. “By looking at multiple targets or watching targets move over time, we can get a much better view of what’s actually happening within complex living systems,” Cutrale said.

HySP was developed at the University of Southern California’s Translational Imaging Center, known for its use of advanced imaging to study developing embryos and disease patterns of Multiple Sclerosis and Alzheimer’s Disease.

Follow the link below to read about the complex development process and long terms prospects of HySP.

As a Senior Writer for TriMed Media Group, Will covers radiology practice improvement, policy, and finance. He lives in Chicago and holds a bachelor’s degree in Life Science Communication and Global Health from the University of Wisconsin-Madison. He previously worked as a media specialist for the UW School of Medicine and Public Health. Outside of work you might see him at one of the many live music venues in Chicago or walking his dog Holly around Lakeview.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.